337 related articles for article (PubMed ID: 31016522)
21. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
[TBL] [Abstract][Full Text] [Related]
22. New algorithm for OHSS prevention.
Papanikolaou EG; Humaidan P; Polyzos N; Kalantaridou S; Kol S; Benadiva C; Tournaye H; Tarlatzis B
Reprod Biol Endocrinol; 2011 Nov; 9():147. PubMed ID: 22054506
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
[TBL] [Abstract][Full Text] [Related]
24. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
[TBL] [Abstract][Full Text] [Related]
25. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
26. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
[TBL] [Abstract][Full Text] [Related]
27. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'.
Ling LP; Phoon JW; Lau MS; Chan JK; Viardot-Foucault V; Tan TY; Nadarajah S; Tan HH
Reprod Biomed Online; 2014 Sep; 29(3):392-4. PubMed ID: 25042608
[TBL] [Abstract][Full Text] [Related]
28. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.
Fatemi HM; Garcia-Velasco J
Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome--a 20-year experience.
Kol S; Itskovitz-Eldor J
Semin Reprod Med; 2010 Nov; 28(6):500-5. PubMed ID: 21082509
[TBL] [Abstract][Full Text] [Related]
30. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
31. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
32. Effect of GnRH agonist alone or combined with different low-dose hCG on cumulative live birth rate for high responders in GnRH antagonist cycles: a retrospective study.
He Y; Tang Y; Chen S; Liu J; Liu H
BMC Pregnancy Childbirth; 2022 Mar; 22(1):172. PubMed ID: 35236312
[TBL] [Abstract][Full Text] [Related]
33. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.
Castillo JC; Haahr T; Martínez-Moya M; Humaidan P
Ups J Med Sci; 2020 May; 125(2):131-137. PubMed ID: 32366146
[TBL] [Abstract][Full Text] [Related]
34. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
35. Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome.
Kasum M; Orešković S; Franulić D; Čehić E; Lila A; Vujić G; Grgić F
Acta Clin Croat; 2017 Mar; 56(1):133-142. PubMed ID: 29120551
[TBL] [Abstract][Full Text] [Related]
36. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
37. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.
Tehraninejad ES; Nasiri R; Rashidi B; Haghollahi F; Ataie M
Arch Gynecol Obstet; 2010 Sep; 282(3):319-25. PubMed ID: 20379731
[TBL] [Abstract][Full Text] [Related]
38. Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome.
Shrem G; Steiner N; Balayla J; Volodarsky-Perel A; Tannus S; Son WY; Dahan MH
Reprod Biomed Online; 2019 Sep; 39(3):433-438. PubMed ID: 31320288
[TBL] [Abstract][Full Text] [Related]
39. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
40. Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise.
Friis Wang N; Skouby SO; Humaidan P; Andersen CY
Hum Reprod; 2019 May; 34(5):942-948. PubMed ID: 30927415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
